Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics September 06, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax Reports Second Quarter Financial Results and Provides Business Update August 11, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules August 01, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis June 05, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update April 17, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax to Present at BIO-Europe Spring March 16, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax Presenting at BIO CEO & Investor Conference February 02, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study January 23, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study January 06, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax to Present at Biotech Showcase 2023 January 05, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax CEO Issues Letter to Shareholders December 30, 2022 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax Announces Closing of $8 Million Underwritten Public Offering December 20, 2022 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax Announces Pricing of $8 Million Underwritten Public Offering December 16, 2022 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board December 06, 2022 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update November 30, 2022 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy November 29, 2022 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences November 15, 2022 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Tickers BVXV Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.